254 results about "Use medication" patented technology

The invention provides an inhalation medication auxiliary device, relates to the technical field of medical instruments, and solves the technical problem that a large force is needed when a puncture part of an inhaler is pressed to puncture a capsule. The inhalation medication auxiliary device comprises a shell and an automatic puncturing module, and the shell covers an inhaler and is used for fixing the inhaler; the automatic puncturing module is arranged on the shell and used for automatically puncturing the capsule placed in the inhaler. According to the embodiment of the invention, the automatic puncturing of the capsule in the inhaler is realized through the automatic puncturing module arranged on the shell, so that the technical problems that large force is needed when the puncturing part of the inhaler is pressed to puncture the capsule, a user with weak force is difficult to press, and the inhaler is not friendly to old and young users are solved.

The invention belongs to the field of pharmaceutical preparations. The invention relates to a novel dosage form of an isavuconazole sulfate freeze-dried tablet, and a prescription and a process for preparing the isavuconazole sulfate freeze-dried tablet by adopting a freeze-drying method. The isavuconazole sulfate freeze-dried tablet is prepared from isavuconazole sulfate serving as a main drug and pharmaceutic adjuvants. Water is not needed during taking, and the tablet can be rapidly disintegrated after being put in the mouth and is suitable for patients with dysphagia such as old people and children; the production process of the isavuconazole sulfate freeze-dried orally disintegrating tablet is simple in technology, easy to control and suitable for industrial production.

The invention discloses application of tangeretin in preparation of a medicine for treating hearing loss. The invention proposes and verifies that the tangeretin can effectively protect the spiral ganglion neurons for the first time, and avoids the death of the cells caused by cisplatin medication; experimental data show that the preventive tangeretin drug can effectively prevent hearing loss of adult mice and greatly relieve sensorineural deafness caused by cis-platinum, and a new thought is provided for clinical ototoxicity drug administration.

The invention discloses application of compound resina draconis in preparation of a medicine for treating acute myocardial infarction. The compound resina draconis has the effects of resisting free radical oxidation and platelet aggregation, expanding coronary artery, inhibiting increase of myocardial enzymology CPK and LDH and reducing myocardial oxygen consumption, so that the myocardial infarction range is reduced, and myocardial ischemic ST segment elevation is improved; the compound is combined with aspirin for treating acute myocardial infarction, and the compound and aspirin have a synergistic effect, play a role in resisting platelet aggregation and inhibit synthesis of thromboxane A2, and show a good ischemic myocardial protection effect. Meanwhile, according to the technical scheme that the compound resina draconis is used independently or combined with aspirin, the application range of the medicine is widened, contribution is made for research and development of the medicine for relieving side effects caused by aspirin treatment, and the application prospect is good.

This application relates to a rifapentine-containing pharmaceutical composition and its preparation method. The rifapentine-containing granules are prepared by dry granulation, which reduces the content of impurities present in existing pharmaceutical compositions, especially the content of the genotoxic impurity 1-cyclopentan-4-nitrosopiperazine, thereby improving the safety and efficacy of the drug.

The invention relates to the technical field of medicines, in particular to a briracetam oral solution and a preparation method thereof. According to the present invention, by adjusting the formula and the preparation process of the oral solution of the briracetam, the stability of the briracetam is effectively improved, the antibacterial effect is effectively improved without adding the preservative, the taste of the oral solution is adjusted, and the medication compatibility of children patients is improved.

The invention provides a method for treating AR negative TNBC through combination of quercetin and enzalutamide, the quercetin up-regulates the AR expression level by inhibiting a high-expression solute carrier SLC7A5, so that tumor cells which are not sensitive to enzalutamide originally obtain drug sensitivity again; the combined use of an AR antagonist enzalutamide (1-80 [mu] M) can cooperatively block an AR signal channel and significantly inhibit cell proliferation (the inhibition rate of drug combination is 70%, Plt, 0.01 higher than that of a single drug). In-vitro experiments prove that the scheme has a synergistic effect (the effect is optimal when the mass ratio is 1: 1-5: 1) in MDA-MB-231 cells, and an animal model shows that the tumor volume inhibition rate reaches 70% or above. Safety evaluation shows that the drug combination does not cause abnormity of serum biochemical indexes (ALT / AST / BUN / CREA) or damage of main organs and tissues. The invention further provides a preparation method of an oral preparation (tablets / capsules / nanoparticles) containing quercetin (50-500 mg / day) and enzalutamide (40-160 mg / day), and a new strategy is provided for reversing AR-TNBC drug resistance.

Disclosed are an anthracycline compound, a preparation method therefor, an intermediate, and a use thereof. The present invention provides an anthracycline compound as shown in formula I or a pharmaceutically acceptable salt thereof. The anthracycline compound provided by the present invention has antitumor activity comparable to existing anthracycline drugs (such as nemorubicin) or greater than that of existing anthracycline drugs doxorubicin and daunorubicin, and does not form an oxazole ring structure during metabolism, thereby improving the clinical safety of such drugs.

The application belongs to the technical field of pharmaceutical preparations, and discloses a trimetazidine hydrochloride tablet and a preparation process thereof.The trimetazidine hydrochloride tablet is composed of trimetazidine hydrochloride, lactose, microcrystalline cellulose, sodium crosslinked carboxymethyl cellulose and other auxiliary materials, and specific auxiliary components are added simultaneously.The preparation process comprises the following steps in sequence: pretreatment of core components, inclusion and dispersion, mixing of soft materials, granulation, drying, total mixing and tablet pressing, and the solubility and dispersibility of the drug are effectively improved.The trimetazidine hydrochloride tablet can realize rapid and sufficient release of the drug, has excellent content uniformity, provides precise and stable dose guarantee for clinical medication, and meets the clinical treatment requirements.

To provide a clothing-integrated medicine case that enables a user to always carry medicine on his / her person so as to reduce forgetting to take medicine or searching for a place to put it and to reduce the time and effort required to transfer medicine to another bag when going out. [Solution] This device is designed to allow commonly used medications to be carried around by placing them in an inner pouch i inside multiple square-shaped pockets b attached to clothing a. When taking medication, the user looks at the letters written in each square, removes the inner pouch from the pocket, and takes the medication. Since the letters e and f written on the pocket are close to the eyes when it is time to take the medication, the user is less likely to forget to take the medication.

The application belongs to the field of traditional Chinese medicines, and particularly relates to a new use of a Mailuoshutong preparation, namely, a use of the Mailuoshutong preparation in preparation of a medicine for treating anal fistula. The Mailuoshutong preparation is mainly prepared from Huangqi, Jinyinhua, Huangbai, Cangzhu, Yiyiren, Xuanshen, Danggui, Baishao, Gancao, Shuiji, Wugong and Quanxie. The clinical use result shows that the Mailuoshutong preparation (granules / pills) has a high effective rate in treating anal fistula, can obviously improve the clinical symptoms of the patients with anal fistula, and reduce the pain of the patients, thereby providing a new drug selection for the patients with anal fistula.

The application discloses a composition containing a peripheral vasodilator and a 5alpha-reductase inhibitor, effectively solves the transdermal inhibition of the peripheral vasodilator on the 5alpha-reductase inhibitor by adding a specific penetration enhancer, improves the transdermal rate of the active ingredients in the pharmaceutical composition by proportion adjustment, greatly improves the synergistic effect of local combined medication, avoids the side effects brought by oral 5alpha-reductase inhibitor, and improves the safety of the medicine.

The invention discloses a medical biological dressing suppository matrix and a preparation method thereof, and relates to the technical field of suppositories, the medical biological dressing suppository matrix is prepared by taking gelatin, glycerol, polyethylene glycol derivatives and chitosan quaternary ammonium salt as raw materials, the biocompatibility of the suppository matrix is good, and stimulation and anaphylactic reaction cannot be generated on a medication cavity; and after the suppository matrix is dissolved in the cavity, a film with good adhesion can be formed on the mucous membrane of the cavity, so that the released medicine is fully contacted with the focus for a long time, the curative effect and bioavailability of the medicine are improved, and the suppository is suitable for preparing suppositories for treating gynecological diseases, anorectal diseases and prostate diseases.

The invention provides a memantine derivative or a stereoisomer, a solvate or a pharmaceutically acceptable salt thereof, a pharmaceutical composition of the memantine derivative, and application of the memantine derivative in preparation of drugs for preventing and / or treating central nervous diseases, especially Alzheimer's disease, Parkinson's disease or other neurodegenerative diseases. The compound disclosed by the invention is small in water solubility, can be well prepared into a suspension preparation, has a relatively low dissolution speed in a living body, can achieve the effect of lasting the drug effect for several weeks after single administration, reduces the medication frequency of a patient, improves the compliance of the patient, also ensures the curative effect, and has a relatively good application prospect.

The invention relates to a composition for preventing or treating oral inflammation or oral ulcer, and belongs to the technical field of oral care medicines. The technical scheme of the invention is as follows: the composition contains one or more of lactose-N-trisaccharide and fucosyllactose, and / or lactose-N-tetrasaccharide (Lacto-N-tetraose, LNT) and / or lactose-N-neotetrasaccharide (Lacto-N-neotetraose, LNnT), and the preparation method of the composition comprises the following steps of: mixing the lactose-N-trisaccharide, the fucosyllactose and the lactose-N-tetraose and the lactose-N-neotetraose. According to the technical scheme, the problems that (1) sticking occurs in the tabletting process, and tablets with smooth surfaces cannot be prepared are solved, and (2) the stability problem of buccal tablets in the storage process is stabilized, and the stable and effective composition for treating or preventing inflammation is provided.

This invention relates to a highly active effective fraction of the Epiglottis-Clearing Decoction and its application in the preparation of antitussive drug compositions, belonging to the field of traditional Chinese medicine extract technology. The effective fraction contains hydroxysaffron yellow A, paeoniflorin, naringin, and neohesperidin, with the total content of these four components not less than 20% of the total mass of the effective fraction. The effective fraction of this invention is prepared by purification with macroporous resin. Compared with the freeze-dried powder of the traditional Epiglottis-Clearing Decoction, the total content of the four active ingredients is increased from 3.32% to 20.87%, achieving a more than 6-fold high-efficiency enrichment. Animal pharmacodynamic experiments show that the antitussive effect of a low dose (275.5 mg / kg) of this effective fraction is comparable to that of the freeze-dried powder of the original decoction (1928 mg / kg), reducing the dosage to about 1 / 7 of the original formula, demonstrating a significant "synergistic effect with reduced dosage" technical effect. The effective active ingredients provided by this invention have a clear content and stable quality, and can be made into modern preparations such as tablets, capsules or granules, solving the problems of large volume, inaccurate dosage and poor patient compliance of traditional decoctions.

The application belongs to the technical field of organic synthesis, and particularly relates to a synthesis method of an indolebufen impurity. The application provides a novel synthesis method of the indolebufen impurity, wherein the compound 8 is prepared through a multi-step reaction. The synthesis method has reasonable process design, simple operation process, low cost, high yield and low cost of raw materials. The application can provide an impurity control sample for the research of drug impurities, thereby promoting the research of drug impurities, improving the quality standard of indolebufen drugs, guaranteeing the medication safety of the public, and having a positive significance.

The invention discloses application of securinine in preparation of a medicine for relieving anxiety disorder of postmenopausal women. Female menopausal related mood disorder diseases are researched by constructing a bilateral ovariectomy mouse model, and mouse anxiety-like behaviors induced by ovariectomy can be quickly relieved within 30 minutes by single administration of a natural product securinine. The invention provides a medicine for treating postmenopausal female anxiety disorder, the medicine takes effect quickly, not only provides a brand new medicine candidate for quick intervention of menopausal related anxiety, but also defines a corresponding medication scheme, and has practical application potential.

The invention patent is titled "Dragon and Cypress Gel," belonging to the pharmaceutical category. The main components of Dragon and Cypress Gel are: Phellodendron bark, earthworm, dragon's blood, Oldenlandia diffusa, Sophora flavescens, and Bletilla striata. In recent years, research on cervicitis and cervical lesions has shown good results using external treatments of traditional Chinese medicine. Vaginal cervical medications are characterized by high local drug concentration, low dosage, and safety and effectiveness, receiving high clinical evaluation. The vagina and cervix have abundant capillaries and lymphatic vessels, and lack clearly defined nerve endings, resulting in minimal pain stimulation for patients during administration. This makes it an effective drug release site for specific diseases such as cervicitis and vaginitis. Traditional Chinese medicine gels are a novel type of external preparation of traditional Chinese medicine. They are made by dissolving or uniformly dispersing traditional Chinese medicine in a gel. These gels adhere tightly to the treatment site for a relatively long time, exhibiting good bioadhesion, and are simple to prepare. It is suitable for use on skin, mucous membranes and cavities. It not only avoids the first-pass effect of enzymes and acids in the gastrointestinal tract that exists in oral administration, but also reduces the adverse reactions of drugs. It has the characteristics of good spreadability, non-greasy feeling, easy to wash off, good transdermal absorption, and comfortable use.

The invention belongs to the technical field of biological medicines, and particularly relates to a group of synergists for anti-tuberculosis infection medicines and application of the synergists. In the invention, Vortioxetine (Vor) shows obvious activity for enhancing mycobacterium infection resistance: under the concentration of 2 mu g / mL, the MIC (minimal inhibitory concentration) of Bedaquiline to H37Rv can be reduced by about 64 times (from 0.06 mu g / mL to 0.0009375 mu g / mL), and the MIC of Bedaquiline to an Rv0678 mutant strain can be reduced by about 64 times (from 1 mu g / mL to 0.0156 mu g / mL). And the content of sertraline hydrochloride (STL) can be reduced by about 16 times and 8 times respectively. The synergistic effect of fluoxetine (FXT) is weakest and is only reduced by two times. The synergist disclosed by the invention is a drug which has been sold on the market, so that the synergist has safety and complete medication guidance. The preparation process and the production process are both perfect, the product can be quickly sold on the market, the selling price is reasonable, the market acceptability is good, and the patient compliance is high. The votioxetine or the sertraline can be used as a synergist of a medicine for resisting mycobacterium tuberculosis infection.

The invention relates to an ibuprofen-containing transdermal patch as well as a preparation method and application thereof. The ibuprofen-containing transdermal patch comprises a polymer matrix layer, the polymer matrix layer comprises ibuprofen, a compound at least containing one amino group and a pressure-sensitive adhesive, and based on the weight of the polymer matrix layer, the ibuprofen accounts for 10-30% by weight, the compound at least containing one amino group accounts for 0.1-5% by weight, and the pressure-sensitive adhesive accounts for 0.1-5% by weight. The weight content of the pressure-sensitive adhesive is 45%-84%, the pressure-sensitive adhesive is composed of a silicone pressure-sensitive adhesive and an acrylate pressure-sensitive adhesive, and the weight ratio of the silicone pressure-sensitive adhesive to the acrylate pressure-sensitive adhesive is 1: 1-15: 1. According to the transdermal patch, the penetration capacity of ibuprofen is remarkably improved, particularly, the early-stage medicine penetration rate is higher, the medicine utilization rate is greatly improved, meanwhile, the patch is good in application performance, free of skin irritation, free of crystallization in the long-term storage process, good in stability and capable of better meeting the clinical medication requirement.

The invention relates to (i) the prevention or treatment of a sleep disturbance, preferably in a patient having neuropathic pain; and / or (ii) the prevention or treatment of neuropathic pain in a patient having a sleep disturbance; and / or (iii) the prevention or treatment of neuropathic pain in a patient having been treated previously and / or being treated concomitantly with an analgesic medication for relief of neuropathic pain, preferably selected from antiepileptics, antidepressants and opioid analgesics, wherein the patient preferably has a sleep disturbance; in either cases by means of one or more high-concentration capsaicin and / or capsaicinoid topical dose units, preferably pharmaceutical patches, comprising capsaicin and / or capsaicinoid at a concentration of at least 2.5 wt.-%, relative to the total weight of dose unit.

The application relates to application of C-methylated high isoflavone compounds in preparation of antitumor drugs and belongs to the technical field of drug application. In order to solve the problem that the existing antitumor activity is not much reported, the application of C-methylated high isoflavone compounds in preparation of antitumor drugs is provided, the C-methylated high isoflavone compounds are selected from compounds shown in the following formula 1 or formula 2: the C-methylated high isoflavone compounds or pharmaceutically acceptable salts thereof are used as active ingredients for preparation of antitumor drugs for preventing and / or treating adrenal pheochromocytoma (PC-12) and / or human brain astrocytoma (U-87MG). The C-methylated high isoflavone compounds have the advantages of high activity and high inhibition capacity, can be extracted from polygonatum sibiricum and have good drug safety.

This invention discloses the application of low-concentration topical anesthetics in ophthalmic surgery, relating to the field of low-concentration topical anesthetic application technology, including the following specific application process: confirming the patient's basic surgical condition before administration; selecting anesthetic drugs and optimizing the administration concentration; performing administration according to the specific situation; real-time dynamic monitoring and adjustment of the administration dosage; gradually reducing the drug and transitioning to withdrawal. This invention improves drug safety and patient compliance while ensuring analgesic effects by optimizing anesthetic drug concentration and administration method. Furthermore, by using topical anesthetics at concentrations lower than conventional anesthetics for local administration after ophthalmic surgery, it can effectively relieve postoperative pain, discomfort, and foreign body sensation while significantly reducing toxic effects on corneal epithelial cells, reducing delayed corneal healing, dry eye, and corneal damage. It is effectively applicable to analgesia management after pterygium excision, refractive surgery, and other common ophthalmic surgeries, and has good clinical application value.

This invention discloses the application of quinolinic acid in the preparation of drugs for the prevention and treatment of acute kidney injury (AKI). AKI refers to acute kidney injury induced by renal ischemia-reperfusion. The drug is an oral formulation used for prophylactic administration in high-risk individuals undergoing iatrogenic procedures at potential AKI risk, and for pretreatment of ischemic conditions in transplanted kidneys. Experiments have shown that administration of quinolinic acid significantly reduces serum urea nitrogen levels in AKI mice, alleviates renal tissue morphological damage in AKI mice, and reduces the expression level of the renal tubular injury factor NGAL protein in AKI mice, demonstrating significant clinical value in the prevention and treatment of AKI.

The invention belongs to the technical field of medicines, and particularly relates to application of tyrosol in preparation of a medicine for preventing and treating radioactive intestinal injury. The CAS number of the tyrosol provided by the invention is 501-94-0, and SMILES is C1 = CC (= CC = C1CCO) O; the radioactive intestinal injury is intestinal injury caused by ionizing radiation and comprises acute radioactive intestinal injury and chronic radioactive intestinal injury. An animal model is utilized, it is proved from the cellular level that the tyrosol can be used for preventing and treating the radioactive intestinal injury, safety is high, the tyrosol is suitable for acute radiation disease patients, nuclear employees, astronauts, radiotherapy patients and the like, the tyrosol can be used before treatment or during task execution, and a new medicine choice is provided for preventing and treating the radioactive intestinal injury.

The present invention relates to the use of an anti-interleukin-6 agent prior to, simultaneously with, or after a CRS inducing immunotherapeutic agent.

The application discloses an anticancer composition of combined medication, and application of the composition in preparation of an anticancer drug. The combined medication composition provided by the application comprises a PARP inhibitor, Olaparib, and a calcium ion antagonist, Amlodipine maleate, and the two components have a synergistic effect, have higher sensitivity to gastric cancer compared with a single PARP inhibitor, and significantly improve the effective rate, thereby having a wide application prospect. The Amlodipine in the combined medication composition provided by the application enhances the curative effect of the PARP inhibitor, Olaparib, on gastric cancer.

The invention discloses a novel compound preparation for resisting mycobacterium tuberculosis and a preparation method thereof.The compound preparation comprises glutathione active part and pyrazinamide, the weight ratio of glutathione to pyrazinamide is (2-4): 5, the glutathione active part comprises glutathione, an isolation stabilizer, a plasticizer, an anti-sticking agent and a first stabilizer, and the first stabilizer comprises glutathione, an isolation stabilizer, a plasticizer, an anti-sticking agent and a second stabilizer. According to the glutathione active part, firstly, a fluidized powder coating technology is adopted, and the relatively unstable active ingredient glutathione is subjected to powder coating; and preparing the coated components, pyrazinamide, a filler, a second stabilizer, an adhesive, a disintegrating agent and a lubricant into a specific preparation. According to the preparation, the hepatotoxicity during pyrazinamide medication is reduced, the compliance is increased, and meanwhile, the technical problem that a pyrazinamide glutathione preparation is unstable is solved.